Live feed08:00:00·7dPRReleasevia QuantisnowGossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA ApprovalByQuantisnow·Wall Street's wire, on your screen.GOSS· Gossamer Bio Inc.Health Care
